5-ethyl-2′-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil

被引:6
作者
Kralovánszky, J
Katona, C
Jeney, A
Pandi, E
Noordhuis, P
Erdelyi-Toth, V
Ötvös, L
Kovács, P
Van der Wilt, CL
Peters, GJ
机构
[1] Natl Inst Oncol, Dept Clin Res, H-1525 Budapest, Hungary
[2] Semmelweis Univ Med, Inst Pathol & Expt Canc Res 1, H-1085 Budapest, Hungary
[3] Free Univ Amsterdam Hosp, Dept Med Oncol, Amsterdam, Netherlands
[4] Hungarian Natl Acad Sci, Cent Res Inst Chem, H-1026 Budapest, Hungary
[5] Univ Med Sch, Inst Pharmacol, H-4012 Debrecen, Hungary
基金
匈牙利科学研究基金会;
关键词
5-fluorouracil; 5-ethyl-2 '-deoxyuridine; modulation; antitumour activity; pharmacokinetics;
D O I
10.1007/s004320050333
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present studies was to elucidate the effects and optimal modulatory conditions of 5-ethyl-2'-deoxyuridine (EtdUrd) on the antitumour efficacy. pharmacokinetics and catabolism of 5-fluorouracil (5-FU) on Colon-26 and Colon-38 murine tumours. HPLC and GC-MS techniques were used to measure the concentrations of 5-FU, dihydro-5-fluorouracil, EtdUrd, 5-ethyluracil and uridine in the plasma and that of 5-FU and 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) in the tumours. It was shown that EtdUrd, given 1 h before 5-FU, selectively enhanced the antitumour action of 5-FU, without significantly increasing its toxic side-effects, thus resulting in an approximately three times higher therapeutic index. Pharmacokinetic studies revealed that 1 h after 400 mg kg EtdUrd administration - i.e. at the time of 5-FU treatment - the plasma concentration of EtdUrd was 269 mu M, and that of 5-ethyluracil, as the major metabelite of EtdUrd, was 421 mu M. It is of interest that EtdUrd pretreatment did not change the maximal plasma concentration of 5-FU; however, the half-life of the terminal elimination increased from 114.5 min to 171.2 min and thus the mean residence time of 5-FU rose significantly (P < 0.05). After the combined treatment, the maximal concentration of dihydro-5-fluorouracil in the plasma decreased from 61.06 mu M to 29.70 mu M (P < 0.01). The intratumoral concentrations of 5-FU were 34%-158% higher 6-96 h after the combined treatment than after the single 5-FU treatment. EtdUrd also caused a moderate increase in the intratumoral level of FdUMP. It is noteworthy, that EtdUrd increased the endogenous uridine concentration in the plasma from 18 mu M to a maximum of 249 mu M, and the level remained high for longer than 6 h. The present studies indicate that EtdUrd enhances the therapeutic index of 5-FU by reducing the catabolism, prolonging the plasma and intratumoral concentrations of 5-FU and, at the same time, offering protection to normal organs by increasing the endogenous uridine level.
引用
收藏
页码:675 / 684
页数:10
相关论文
共 45 条
[21]   LEVAMISOLE AND FLUOROURACIL FOR ADJUVANT THERAPY OF RESECTED COLON-CARCINOMA [J].
MOERTEL, CG ;
FLEMING, TR ;
MACDONALD, JS ;
HALLER, DG ;
LAURIE, JA ;
GOODMAN, PJ ;
UNGERLEIDER, JS ;
EMERSON, WA ;
TORMEY, DC ;
GLICK, JH ;
VEEDER, MH ;
MAILLIARD, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (06) :352-358
[22]  
MONTGOMERY C A, 1990, Cancer Bulletin (Houston), V42, P230
[23]  
NADAL JC, 1988, BIOMED PHARMACOTHER, V42, P387
[24]   STRUCTURE ACTIVITY RELATIONSHIP OF LIGANDS OF DIHYDROURACIL DEHYDROGENASE FROM MOUSE-LIVER [J].
NAGUIB, FNM ;
ELKOUNI, MH ;
CHA, SM .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (09) :1471-1480
[25]   THYMIDINE CONCENTRATIONS IN SERUM AND URINE OF DIFFERENT ANIMAL SPECIES AND MAN [J].
NOTTEBROCK, H ;
THEN, R .
BIOCHEMICAL PHARMACOLOGY, 1977, 26 (22) :2175-2179
[26]   PROLONGED RETENTION OF HIGH-CONCENTRATIONS OF 5-FLUOROURACIL IN HUMAN AND MURINE TUMORS AS COMPARED WITH PLASMA [J].
PETERS, GJ ;
LANKELMA, J ;
KOK, RM ;
NOORDHUIS, P ;
VANGROENINGEN, CJ ;
VANDERWILT, CL ;
MEYER, S ;
PINEDO, HM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 31 (04) :269-276
[27]   INVITRO BIOCHEMICAL AND INVIVO BIOLOGICAL STUDIES OF THE URIDINE RESCUE OF 5-FLUOROURACIL [J].
PETERS, GJ ;
VANDIJK, J ;
LAURENSSE, E ;
VANGROENINGEN, CJ ;
LANKELMA, J ;
LEYVA, A ;
NADAL, JC ;
PINEDO, HM .
BRITISH JOURNAL OF CANCER, 1988, 57 (03) :259-265
[28]   CLINICAL RELEVANCE OF BIOCHEMICAL MODULATION OF 5-FLUOROURACIL [J].
PETERS, GJ ;
VANGROENINGEN, CJ .
ANNALS OF ONCOLOGY, 1991, 2 (07) :469-480
[29]   SEPARATION OF 5-FLUOROURACIL AND URACIL BY ION-PAIR REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY ON A COLUMN WITH POROUS POLYMERIC PACKING [J].
PETERS, GJ ;
KRAAL, I ;
LAURENSSE, E ;
LEYVA, A ;
PINEDO, HM .
JOURNAL OF CHROMATOGRAPHY, 1984, 307 (02) :464-468
[30]  
PETERS GJ, 1995, PATHS PYRIMIDINES, V3, P21